OPM-383 / Oncodesign - LARVOL DELTA

Unlocking the potential of OPM-383: A novel LRRK2 inhibitor in cancer therapy (AACR 2024) - "This study characterizes a potent first-in-class LRRK2 inhibitor in cancer models. The findings suggest that OPM383 could serve as an attractive lead scaffold for designing and synthesizing a new class of kinase inhibitors for potential applications in cancer therapy."

IO biomarker • Biliary Cancer • Cholangiocarcinoma • Colon Cancer • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • LRRK2 • mTOR